



OPEN ACCESS

EDITED AND REVIEWED BY

Franz Rödel,
University Hospital Frankfurt, Germany

*CORRESPONDENCE

Qin Huo
huoqinszu@163.com
Yizhe Tang
tangyz@email.szu.edu.cn

†Dummy

SPECIALTY SECTION

This article was submitted to
Cancer Immunity
and Immunotherapy,
a section of the journal
Frontiers in Oncology

RECEIVED 28 June 2022

ACCEPTED 04 August 2022

PUBLISHED 22 August 2022

CITATION

Deng T, Liu Y, Zhuang J, Tang Y and
Huo Q (2022) Corrigendum: ASPM is a
prognostic biomarker and correlates
with immune infiltration in kidney
renal clear cell carcinoma and liver
hepatocellular carcinoma.
Front. Oncol. 12:979968.
doi: 10.3389/fonc.2022.979968

COPYRIGHT

© 2022 Deng, Liu, Zhuang, Tang and
Huo. This is an open-access article
distributed under the terms of the
Creative Commons Attribution License
(CC BY). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s)
are credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma

Tingting Deng[†], Yang Liu[†], Jialang Zhuang,
Yizhe Tang* and Qin Huo*

Department of Otolaryngology and Geriatric Medicine, Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen University, Shenzhen, China

KEYWORDS

ASPM, gene expression, prognosis, tumor-infiltrating, biomarker

A corrigendum on

ASPM is a prognostic biomarker and correlates with immune infiltration in kidney renal clear cell carcinoma and liver hepatocellular carcinoma

by Deng T, Liu Y, Zhuang J, Tang Y and Huo Q (2022) *Front. Oncol.* 12:632042.
doi: 10.3389/fonc.2022.632042

In the published article, there was an error in the PDF page header. Instead of “Liu et al”, it should be “Deng et al.”.

In the published article, there was an error in affiliation 1. Instead of “¹Department of Otolaryngology and Geriatric Medicine, Biobank, Shenzhen Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University Health Science Center, Shenzhen Second People's Hospital, Shenzhen, China, ²Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, Shenzhen, China”, it should be “Department of Otolaryngology and Geriatric Medicine, Guangdong Key Laboratory of Systems Biology and Synthetic Biology for Urogenital Tumors, Shenzhen Second People's Hospital, First Affiliated Hospital of Shenzhen University, Health Science Center, Shenzhen University, Shenzhen, China”.

In the published article, there was an error in the Funding statement. One funding source was carelessly missed with the code “ZDSYS20190902093401689”. The funding statement for the Shenzhen STIC Research Foundation should be combined with Shenzhen Science and Technology Innovation Committee since they stand for the same funding agency. The correct Funding statement appears below.

Funding

This work was supported by National Natural Science Foundation of China (82002936); Guangdong Natural Science Foundation (2020A1515010347); Shenzhen Science and Technology Innovation Committee (JCYJ20190806163209126, JCYJ20180228162815750, JCYJ20190806164203496 and ZDSYS20190902093401689); the Major Scientific and Technological Project of Guangdong Province (2020A1515110419); Shenzhen Municipal Government of China (RCBS20200714114856269, JCYJ20210324102807019); China Postdoctoral Science Foundation Funded Project (2021T140478).

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

In the published article, there was an error in the Methods section, Patient Samples & Immunohistochemistry subsections. The second phrase of “20 diagnosed cases of KIRC and 20 control samples” in the same paragraph was a repeat typo and should be corrected as “20 diagnosed cases of LIHC and 20 control samples”.

Two same corrections have been made to Methods, Patient Samples & Immunohistochemistry subsections. This sentence previously stated “as well as 20 diagnosed cases of KIRC and 20 control samples (muscle, lymph nodes)”. It should instead be written as follows: “as well as 20 diagnosed cases of LIHC and 20 control samples (muscle, lymph nodes)”. The patient sample information is correctly displayed in the main text and figures in the published article.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.